Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

Heining, Christoph, Horak, Peter, Uhrig, Sebastian, Codo, Paula L., Klink, Barbara, Hutter, Barbara, Fröhlich, Martina, Bonekamp, David, Richter, Daniela, Steiger, Katja, Penzel, Roland, Endris, Volker, Ehrenberg, Karl Roland, Frank, Stephanie, Kleinheinz, Kortine, Toprak, Umut H., Schlesner, Matthias, Mandal, Ranadip, Schulz, Lothar, Lambertz, Helmut, Fetscher, Sebastian, Bitzer, Michael, Malek, Nisar P., Horger, Marius, Giese, Nathalia A., Strobel, Oliver, Hackert, Thilo, Springfeld, Christoph, Feuerbach, Lars, Bergmann, Frank, Schröck, Evelin, von Kalle, Christof, Weichert, Wilko, Scholl, Claudia, Ball, Claudia R., Stenzinger, Albrecht, Brors, Benedikt, Fröhling, Stefan, Glimm, Hanno·2018·Cancer Discovery

Abstract

We used whole-genome and transcriptome sequencing to identify clinically actionable genomic alterations in young adults with pancreatic ductal adenocarcinoma (PDAC). Molecular characterization of 17 patients with PDAC enrolled in a precision oncology program revealed gene fusions amenable to pharmacologic inhibition by small-molecule tyrosine kinase inhibitors in all patients with KRAS wild-type (KRASWT) tumors (4 of 17). These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberrant ERBB receptor–mediated signaling, and pharmacologic ERBB inhibition resulted in clinical improvement and remission of liver metastases in 2 patients with NRG1-rearranged tumors that had proved resistant to standard treatment. Our findings demonstrate that systematic screening of KRASWT tumors for oncogenic fusion genes will substantially improve the therapeutic prospects for a sizeable fraction of patients with PDAC. Significance: Advanced PDAC is a malignancy with few treatment options that lacks molecular mechanism-based therapies. Our study uncovers recurrent gene rearrangements such as NRG1 fusions as disease-driving events in KRASwt tumors, thereby providing novel insights into oncogenic signaling and new therapeutic options in this entity. Cancer Discov; 8(9); 1087–95. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1047

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-0036

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 240

Metadata

Authors
Heining, C., Horak, P., Uhrig, S., Codo, P. L., Klink, B., Hutter, B., Fröhlich, M., Bonekamp, D., Richter, D., Steiger, K., Penzel, R., Endris, V., Ehrenberg, K. R., Frank, S., Kleinheinz, K., Toprak, U. H., Schlesner, M., Mandal, R., Schulz, L., Lambertz, H., Fetscher, S., Bitzer, M., Malek, N. P., Horger, M., Giese, N. A., Strobel, O., Hackert, T., Springfeld, C., Feuerbach, L., Bergmann, F., Schröck, E., von Kalle, C., Weichert, W., Scholl, C., Ball, C. R., Stenzinger, A., Brors, B., Fröhling, S., & Glimm, H.
Venue
Cancer Discovery
Published
2018-09-01
Volume
8
Issue
9
Pages
1087-1095
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2804827327
Cited by
240
References
8
FWCI
8.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-18-0036
The paper
Heining, C., Horak, P., Uhrig, S., Codo, P. L., Klink, B., Hutter, B., Fröhlich, M., Bonekamp, D., Richter, D., Steiger, K., Penzel, R., Endris, V., Ehrenberg, K. R., Frank, S., Kleinheinz, K., Toprak, U. H., Schlesner, M., Mandal, R., Schulz, L., . . . Glimm, H. (2018). NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-18-0036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.